Adenocarcinoma

"Adenocarcinoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A malignant epithelial tumor with a glandular organization.

Descriptor ID	D000230
MeSH Number(s)	C04.557.470.200.025
Concept/Terms	Adenocarcinoma Adenocarcinoma Adenocarcinomas Adenoma, Malignant Adenomas, Malignant Malignant Adenoma Malignant Adenomas Carcinoma, Granular Cell Carcinoma, Granular Cell Carcinomas, Granular Cell Granular Cell Carcinoma Granular Cell Carcinomas Adenocarcinoma, Granular Cell Adenocarcinomas, Granular Cell Granular Cell Adenocarcinoma Granular Cell Adenocarcinomas Adenocarcinoma, Tubular Adenocarcinoma, Tubular Adenocarcinomas, Tubular Tubular Adenocarcinoma Tubular Adenocarcinomas Carcinoma, Tubular Carcinomas, Tubular Tubular Carcinoma Tubular Carcinomas Carcinoma, Cribriform Carcinoma, Cribriform Carcinomas, Cribriform Cribriform Carcinoma Cribriform Carcinomas Adenocarcinoma, Basal Cell Adenocarcinoma, Basal Cell Adenocarcinomas, Basal Cell Basal Cell Adenocarcinoma Basal Cell Adenocarcinomas Adenocarcinoma, Oxyphilic Adenocarcinoma, Oxyphilic Adenocarcinomas, Oxyphilic Oxyphilic Adenocarcinoma Oxyphilic Adenocarcinomas

Below are MeSH descriptors whose meaning is more general than "Adenocarcinoma".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Neoplasms, Glandular and Epithelial [C04.557.470]
Carcinoma [C04.557.470.200]
Adenocarcinoma [C04.557.470.200.025]

Below are MeSH descriptors whose meaning is related to "Adenocarcinoma".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Adenocarcinoma" by people in this website by year, and whether "Adenocarcinoma" was a major or minor topic of these publications.

Bar chart showing 893 publications over 30 distinct years, with a maximum of 50 publications in 2003

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	20	4	24
1997	23	4	27
1998	32	4	36
1999	35	5	40
2000	28	15	43
2001	28	3	31
2002	29	5	34
2003	41	9	50
2004	25	13	38
2005	36	8	44
2006	28	4	32
2007	28	13	41
2008	29	9	38
2009	22	2	24
2010	20	6	26
2011	36	4	40
2012	30	5	35
2013	23	4	27
2014	39	4	43
2015	33	4	37
2016	24	4	28
2017	27	5	32
2018	19	1	20
2019	15	3	18
2020	14	5	19
2021	18	2	20
2022	16	0	16
2023	16	0	16
2024	12	1	13
2025	1	0	1

Below are the most recent publications written about "Adenocarcinoma" by people in Profiles.

Baraban EG, Vlachou E, Patel S, Kates M, Johnson B, Smith A, Shenderov E, Sharma S, Denmeade SR, Brame A, Han M, De Marzo AM, Matoso A, Hoffman-Censits J. Nectin-4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study. Prostate. 2025 Apr; 85(5):443-447.

View in: PubMed
Li Y, Lam SSK, Gao Y, Shore E, Anderson DW, Hode T, Martin RC. Enhancing the Immunotherapeutic Effect by IP-001 and Irreversible Electroporation in Mouse Oligometastatic Models of Pancreatic Adenocarcinoma. Ann Surg Oncol. 2025 Apr; 32(4):2786-2798.

View in: PubMed
Rencuzogullari A, Karahan SN, Selcukbiricik F, Lacin S, Taskin OC, Saka B, Karahacioglu D, Gurses B, Ozoran E, Uymaz DS, Ozata IH, Saglam S, Bugra D, Balik E. The New Era of Total Neoadjuvant FLOT Therapy for Locally Advanced, Resectable Gastric Cancer: A Propensity-Matched Comparison With Standard Perioperative Therapy. J Surg Oncol. 2025 Mar; 131(3):417-426.

View in: PubMed
Ajmal N, Deng Y, Kenyon LC, Curtis MT, Dispagna M, Izes J, Li L. Metastatic prostate adenocarcinoma to the brain - a clinicopathologic analysis of 21 cases. Diagn Pathol. 2024 Oct 01; 19(1):132.

View in: PubMed
Su SH, Mitani Y, Li T, Sachdeva U, Flashner S, Klein-Szanto A, Dunbar KJ, Abrams J, Nakagawa H, Gabre J. Lactate Suppresses Growth of Esophageal Adenocarcinoma Patient-Derived Organoids through Alterations in Tumor NADH/NAD+ Redox State. Biomolecules. 2024 Sep 22; 14(9).

View in: PubMed
Nadeem MS, Ali U, Khan A, Wajid I, Riaz O, Azeem MT. Response of various histological types of locally advanced rectal cancer to neoadjuvant multimodality therapy. J Pak Med Assoc. 2024 Jul; 74(7):1240-1244.

View in: PubMed
Naranjo NM, Kennedy A, Testa A, Verrillo CE, Altieri AD, Kean R, Hooper DC, Yu J, Zhao J, Abinader O, Pickles MW, Hawkins A, Kelly WK, Mitra R, Languino LR. Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma. Cancer Biol Ther. 2024 Dec 31; 25(1):2364433.

View in: PubMed
Uijterwijk BA, Lemmers DH, Ghidini M, Wilmink H, Zaniboni A, Salvia R, Kito Fusai G, Groot Koerkamp B, Koek S, Ghorbani P, Zerbi A, Nappo G, Luyer M, Goh BKP, Roberts KJ, Boggi U, Mavroeidis VK, White S, Kazemier G, Bj?rnsson B, Serradilla-Mart?n M, House MG, Alseidi A, Ielpo B, Mazzola M, Jamieson N, Wellner U, Soonawalla Z, Cab?s SS, Dalla Valle R, Pessaux P, Vladimirov M, Kent TS, Tang CN, Fisher WE, Kleeff J, Mazzotta A, Suarez Mu?oz MA, Berger AC, Ball CG, Korkolis D, Bannone E, Ferarri C, Besselink MG, Abu Hilal M. The Five Periampullary Cancers, not Just Different Siblings but Different Families: An International Multicenter Cohort Study. Ann Surg Oncol. 2024 Sep; 31(9):6157-6169.

View in: PubMed
Meredith LT, Grenda TR. Putting Wind in the Sails of Neoadjuvant Therapy for Locally Advanced Esophageal Adenocarcinoma: Perioperative Outcomes. Ann Surg Oncol. 2024 Sep; 31(9):5495-5496.

View in: PubMed
Nguyen JK, Harik LR, Klein EA, Li J, Corrigan D, Liu S, Chan E, Hawley S, Auman H, Newcomb LF, Carroll PR, Cooperberg MR, Filson CP, Simko JP, Nelson PS, Tretiakova MS, Troyer D, True LD, Vakar-Lopez F, Weight CJ, Lin DW, Brooks JD, McKenney JK. Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage. Histopathology. 2024 Oct; 85(4):598-613.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement